CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0001824: Weight lossHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1766 Partner-assisted intervention Wiki 0.71
drug2691 Weight Loss Wiki 0.71
drug1777 Patient-only intervention Wiki 0.71
drug1525 Multi Modal Balance Training Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D015431 Weight Loss NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility

Obesity is a major risk factor for mobility problems in older adults and many older adults use a walking aid to help with their mobility. The use of a walking aid changes normal walking patterns and makes walking harder, leading people to have more functional problems. The purpose of this study is to test the effects of 12 months of a multi-modal balance intervention (MMBI) with supervised weight loss compared to MMBI only on fitness, functional performance, balance, and economy of gait. Participants will be one of 120 participants in the VAMHCS. Participation in this study is voluntary. The research will be conducted at the VAMHCS. The entire study will take approximately 4 years to complete. Subjects' participation in the study will last 24 months.

NCT02806336 Obesity Dysmobility Behavioral: Multi Modal Balance Training Behavioral: Weight Loss
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Distance walked during the 6 minute walking test

Measure: Change in 6 minute walk distance

Time: baseline, 3 months, 6 months, 12 months, 24 months

Secondary Outcomes

Description: VO2peak measured during graded exercise treadmill test to volitional fatigue

Measure: Change in VO2peak

Time: baseline, 6 months, 12 months, 24 months

Description: 6 minute walk with submaximal assessment of oxygen uptake.

Measure: Change in 6 minute walk with VO2 measurement

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: DXA scan

Measure: Change in Muscle mass/body composition as assessed by DXA scan

Time: baseline, 6 months, 12 months, 24 months

Description: LLDFI Questionnaires

Measure: Change in Quality of Life, LLDFI

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Gait biomechanics as assessed by walking mechanics on the GAITmat

Measure: Change in gait biomechanics

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Component scores of the standing balance battery, usual gait speed, and repeated chair stands (which make up the short physical performance battery test); as well as overall short physical performance battery score

Measure: Change in short physical performance battery

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Dynamic test of balance involving change in stepping direction.

Measure: Change in four square step test

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Time to get up from a chair and walk around a cone 8 feet away and sit back down, representing agility.

Measure: Change in 8 foot up and go

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: CT scan

Measure: Change in Muscle mass/body composition as assessed by CT scan

Time: baseline, 6 months, 12 months, 24 months

Description: Self-reported ability to complete activities of daily living and independent activities of daily living.

Measure: Change in ADL/IADL questionnaire

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Self-reported physical activities questionnaire.

Measure: Change in CHAMPS questionnaire

Time: baseline, 3 months, 6 months, 12 months, 24 months

Description: Questionnaire assessing global cognitive function

Measure: Change in MoCA

Time: baseline, 3 months, 6 months, 12 months, 24 months

2 Using Partners to Enhance Long-Term Weight Loss

This study involves an evaluation of the role of domestic partner support in a comprehensive weight loss initiation and maintenance program.

NCT03801174 Obesity Behavioral: Partner-assisted intervention Behavioral: Patient-only intervention
MeSH:Weight Loss
HPO:Decreased body weight Weight loss

Primary Outcomes

Description: Measured on a calibrated, digital scale to the nearest 0.1 kg, assessed every 6 months with 24 months as primary endpoint

Measure: Body weight (kg)

Time: 24 months

Secondary Outcomes

Description: average estimated daily intake from ASA24 Dietary Assessment Tool, assessed every 6 months with 24 months as primary endpoint

Measure: Caloric intake (kcal)

Time: 24 months

Description: average daily minutes of moderate activity over past 7 days from Fitbit, assessed every 6 months with 24 months as primary endpoint

Measure: Physical activity

Time: 24 months

Other Outcomes

Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

Measure: Transformation of motivation for diet

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

Measure: Outcome efficacy for diet

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

Measure: Couple efficacy for diet

Time: 3 months

Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

Measure: Social support for diet

Time: 3 months

Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

Measure: Use of communal coping strategies for diet

Time: 3 months

Description: Score based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)

Measure: Transformation of motivation for physical activity

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)

Measure: Outcome efficacy for physical activity

Time: 3 months

Description: 5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)

Measure: Couple efficacy for physical activity

Time: 3 months

Description: 9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)

Measure: Social support for physical activity

Time: 3 months

Description: 5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)

Measure: Use of communal coping strategies for physical activity

Time: 3 months


HPO Nodes


HP:0001824: Weight loss
Genes 324
FANCE NALCN CBL DNAJC13 HTT TTR PDX1 COL6A2 BIRC3 ABCC8 NAB2 JAK2 SDHB CEP152 SDHAF2 GBA FANCL VHL PTEN STAT5B RFWD3 PMS2 POLG EPCAM POLG NF1 TP53 SDHB SCNN1A MEFV TP53 IL12A-AS1 SLC11A1 CTLA4 KCNJ11 ATRX MLX BRIP1 GPR35 PTEN THPO STAT3 PML TYMP IGH RRM2B HLCS HSPG2 CCR1 MALT1 SDHD GPC3 MLH3 RRM2B MSH2 CCND1 KLRC4 KCNJ18 SDHC SDHC FH JPH3 FANCF TSHR GIGYF2 POLG PALLD HLA-B TCF4 CDKN2A RUNX1 EDN3 BCOR SDHB BRCA2 ERCC3 NOD2 HLA-DRB1 KRT1 PRNP GJA1 BCL10 IRF2BP2 MRAP BCL6 SUCLA2 RHBDF2 FANCG B2M BCL2 ZBTB16 SNCA SLX4 PALB2 KIF1B HLA-DQA1 SCNN1A TGFBR2 KCNJ11 KRAS SDHD SDHA SMAD4 HLA-B INS FANCI POU6F2 UNC80 DAXX C4A IKZF1 CNTNAP1 ATM LIPA UBAC2 FANCD2 NUMA1 COL6A1 LRP12 FANCA RARA RB1 MST1 SLC39A4 EPAS1 PTPN22 SEMA4A KRT10 TRPV4 PCNT F5 SLC25A11 EWSR1 XRCC2 TRIM28 GALC NDP VPS35 MPL AK2 FIP1L1 ASXL1 CDC73 WT1 WT1 TXNRD2 SEMA3D HLA-DPB1 UBE2T TP53 HLA-DPA1 ERCC4 MPL TRIM28 TLR4 NPM1 SCNN1B ACAT1 PIK3CA GDNF SDHD FAN1 FANCB PLA2G6 FAS HLA-DQB1 CENPE RAD51 STAR ERCC5 CHEK2 SDHD IL12A IGH RET LPIN2 FANCM SLC6A8 ERCC4 SNCA SDHAF1 CRLF1 DLST REST PANK2 SLC9A6 SDHA PRKAR1A LRRK2 EDNRB BMPR1A FLI1 CACNA1S TET2 TET2 ABCC8 PTEN MC2R ATP7B ERCC4 UNC80 GNPTAB NABP1 ATRIP IL10 IFNGR1 IL12B GCK SCNN1G HLA-DRB1 STAT4 RNF168 ZFP57 COL6A3 IL23R BMPR1A COL12A1 DIS3L2 ERAP1 FOXP1 CACNA1S STAT3 STAT6 CALR VPS13A MPL MAFB CENPJ TSHR WT1 BRCA1 TRIP13 NNT TP53 RAD51C BRCA2 AKT1 COL5A1 BTNL2 TBL1XR1 GJB4 CCND1 PTPN22 MSH6 PMS1 ERCC2 PRNP GJB3 TYMP NOS1 JPH3 TMEM127 ACADM GATA2 SDHB BRCA1 CYP24A1 LMNA PRTN3 MLH1 MDH2 SRSF2 DNMT3A HLA-B IGH KRAS DCTN1 BRCA2 JAK2 HMGCL MAD2L2 RET FANCC COL1A1 PLK4 PRNP GATA4 ECE1 AVP FOXP3 TRIM37 PLAGL1 HMBS RBBP8 NOD2 DCTN1 KDSR SEMA3C PIK3R1 MAX SCNN1G KIF1B RPS20 JAK2 GALT COL5A2 RET NRTN H19 CFTR ATR TRAIP KCNJ18 HLA-DQB1 HLA-DRB1 PSAP CDH23 EIF2AK3 MECP2 BTK HLA-DRB1 HYMAI IL6 EIF4G1 CUL4B NBN TGFB1 PALB2 VHL SCNN1B HAVCR2 TET2 JAK2 GABRA3
Protein Mutations 2
I148M P12A